Competing Risk of Death and End-stage Renal Disease in Incident Chronic Kidney Disease (Stages 3 to 5): the EPIRAN Community-based Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Kidney Diseases
- Sponsor
- Central Hospital, Nancy, France
- Enrollment
- 631
- Primary Endpoint
- annual incidence rate of CKD
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed.
Methods: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, investigators determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Investigators also described the primary care, outcomes and risk factors associated with outcomes using competing risks analyses for these CKD patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\>= 18 years
- •first serum creatinine value ≥1.7 mg/dL reached after January 1st, 2004
- •and present for at least 3 months
- •residing in the given geographical area (the Urban Community of Greater Nancy (UCGN))
Exclusion Criteria
- •\<18 years
- •prevalent CKD patient : CKD diagnosis before January 1st, 2004
- •patients on dialysis or renal transplanted
- •refusal of participation
Outcomes
Primary Outcomes
annual incidence rate of CKD
Time Frame: inclusion
number of patients residing in a well-defined geographical area having a first serum creatinine value ≥1.7 mg/dL after January 1st, 2004 and still present for at least 3 months
Secondary Outcomes
- dialysis initiation(through study completion, 6 year after study start)
- death(through study completion, 6 year after study start)
- management of CKD patients(through study completion, 6 year after study start)